Pixelgen Technologies has successfully closed an oversubscribed Series B financing round, securing $15.5 million to advance its cellular analysis platform. The funding, led by new investor Flat Capital, will accelerate the global commercialization of the company's Proxiome Kit. This investment aims to expand Pixelgen's market presence and bring its molecular mapping technology to more researchers worldwide.
Strategic Investment for Global Expansion
The financing round raised approximately SEK 150 million, equivalent to $15.5 million, showing strong investor confidence in the company's vision. New investor Flat Capital led the round, with continued participation from existing backers Industrifonden and Navigare Ventures. These funds are earmarked to scale the company's commercial operations and establish a stronger foothold in key international markets.
According to CEO Simon Fredriksson, this capital provides the resources to meet growing demand for their technology. The company plans to expand its team, enhance its product portfolio, and broaden the platform's applications. This support will be crucial in bringing molecular cell architecture analysis to a wider scientific audience.
Innovating Cellular Research with Proxiome Technology
Pixelgen's Proxiome Kit represents a significant leap in cellular research, offering the first high-throughput platform for mapping molecular cell architecture. It provides scientists with an unprecedented view of cellular organization at nanoscale resolution. This innovative tool enables a deeper understanding of fundamental cell functions and complex disease mechanisms.
Unlike conventional proteomic methods that measure protein abundance, the Proxiome Kit reveals how proteins are organized and localized. Powered by the Proximity Network Assay, it captures the architectural features of individual cells. This provides insights into cell state and treatment responses that abundance measurements alone cannot capture.
The technology is poised to unlock new discoveries in critical research areas like cancer, immunology, and autoimmune diseases. Rickard El Tarzi of Flat Capital highlighted its potential to identify novel biomarkers and broaden our understanding of basic biology. By analyzing cellular structure, researchers can investigate disease mechanisms in an entirely new way.
Strengthening Leadership with New Board Appointments
In conjunction with the financing, Pixelgen has strengthened its board of directors with two distinguished industry leaders. Rickard El Tarzi and Ramon Felciano will provide strategic guidance as the company enters its next growth phase. Their collective expertise will be instrumental in scaling the life sciences technology company.
Rickard El Tarzi, CEO of lead investor Flat Capital, brings extensive experience in strategic development and global commercialization. His previous role as Chief Strategy & Product Officer at Olink Proteomics saw him guide the company through a successful IPO. This background is well-suited to help Pixelgen scale its research platform on a global stage.
Ramon Felciano is a respected technology entrepreneur who founded Ingenuity Systems, a pioneer in AI-driven genome interpretation. He will assist Pixelgen in building its digital capabilities, translating the platform's technical differentiation into a competitive advantage. His expertise in software and data strategy will be a significant asset for the company's development.
This $15.5 million Series B financing and the strategic addition of experts to its board mark a pivotal moment for Pixelgen Technologies. The company is now strongly positioned to accelerate the global adoption of its groundbreaking molecular cell architecture platform. With enhanced resources and leadership, Pixelgen is set to make significant contributions to cellular biology and disease research.